SiBone (NASDAQ:SIBN) Stock: Insider Anshul Maheshwari Sells 3,738 Shares

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 3,738 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $22.50, for a total value of $84,105.00. Following the transaction, the insider owned 214,497 shares in the company, valued at $4,826,182.50. The trade was a 1.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total value of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total value of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Stock Up 17.6%

NASDAQ:SIBN opened at $23.77 on Wednesday. SiBone has a 1-year low of $11.48 and a 1-year high of $23.93. The company has a 50-day moving average of $19.50 and a 200 day moving average of $16.48. The firm has a market cap of $1.05 billion, a PE ratio of -76.67 and a beta of 0.64. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. As a group, research analysts anticipate that SiBone will post -0.40 EPS for the current fiscal year.

Key Headlines Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Q3 results topped expectations. SI-BONE reported a loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million slightly exceeded estimates and grew 14.5% year over year. Si-BONE Q3 earnings
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume rose about 20%, and the active U.S. physician base expanded 16% to 1,770. Adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow was $5.9 million. The company also cited new product and reimbursement developments that could support adoption. SI-BONE Q3 results and guidance
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. UBS lifted its target to $26 from $25. TD Cowen raised its target to $23 from $20, though that target is below the recent share price. UBS analyst rating
• Neutral Sentiment: 2026 revenue guidance was reaffirmed. SI-BONE forecast revenue of $231 million to $233 million, close to the $232.2 million consensus, so the outlook offered little change from expectations. The company reported a $3.6 million net loss and remains unprofitable.
• Negative Sentiment: Two insiders sold shares. SVP Michael Pisetsky sold 29,665 shares, and Anshul Maheshwari sold 3,738 shares. Both retained sizable holdings, but the sales may weigh modestly on sentiment. Insider sale filing

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Versant Capital Management Inc increased its position in SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares in the last quarter. D.A. Davidson & CO. lifted its stake in shares of SiBone by 2.8% during the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock worth $711,000 after buying an additional 1,038 shares during the period. State of Wyoming grew its holdings in shares of SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after buying an additional 4,490 shares during the last quarter. Quantinno Capital Management LP grew its holdings in shares of SiBone by 58.2% during the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after buying an additional 10,848 shares during the last quarter. Finally, Inceptionr LLC purchased a new stake in shares of SiBone during the first quarter valued at $156,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on SIBN shares. Truist Financial boosted their price objective on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Needham & Company LLC dropped their target price on SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday. UBS Group lifted their price target on SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Finally, Citigroup restated a “market outperform” rating on shares of SiBone in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.00.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.